Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins

J Virol. 1992 Aug;66(8):5100-5. doi: 10.1128/JVI.66.8.5100-5105.1992.

Abstract

The E6 oncoproteins encoded by the cancer-associated human papillomaviruses (HPVs) can associate with and promote the degradation of wild-type p53 in vitro. To gain further insight into this process, the ability of HPV-16 E6 to complex with and promote the degradation of mutant forms of p53 was studied. A correlation between binding and the targeted degradation of p53 was established. Mutant p53 proteins that bound HPV-16 E6 were targeted for degradation, whereas those that did not complex HPV-16 E6 were not degraded. Since the HPV-16 E6-promoted degradation involves the ubiquitin-dependent proteolysis pathway, specific mutations were made in the amino terminus of p53 to examine whether the E6 targeted degradation involved the N-end rule pathway. No requirement for destabilizing amino acids at the N terminus of p53 was found, nor was evidence found that HPV-16 E6 could provide this determinant in trans, indicating that the N-terminal rule pathway is not involved in the E6-promoted degradation of p53.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Binding Sites
  • Humans
  • Mutagenesis, Site-Directed*
  • Oligodeoxyribonucleotides
  • Oncogene Proteins, Viral / genetics
  • Oncogene Proteins, Viral / metabolism*
  • Papillomaviridae / genetics
  • Papillomaviridae / metabolism
  • Polymerase Chain Reaction
  • Protein Biosynthesis
  • Rabbits
  • Repressor Proteins*
  • Reticulocytes / metabolism
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • E6 protein, Human papillomavirus type 16
  • Oligodeoxyribonucleotides
  • Oncogene Proteins, Viral
  • Repressor Proteins
  • Tumor Suppressor Protein p53